CA15-3 is a useful serum tumor marker for diagnostic integration of hydrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. by Incoronato, M. et al.
Incoronato et al. BMC Cancer 2014, 14:356
http://www.biomedcentral.com/1471-2407/14/356RESEARCH ARTICLE Open AccessCA15-3 is a useful serum tumor marker for
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tomography with integrated computed
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patients
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Background: The aim of this study was to evaluate the value of CA15-3 for the diagnostic integration of molecular
imaging findings performed with hybrid positron emission tomography and computed tomography (PETCT)
technology.
Methods: We retrospectively selected 45 patients with a median age of 60 years (range 39–85 years) and a
previous history of breast cancer (BC) who had already been treated with surgery and other treatments. Three
measurements of CA15-3 were collected within 1 year before PETCT examination, at 6–9 months 3–6 months and
0–3 months before PETCT. The prolonged clinical outcome or imaging follow-up was used to define disease
relapse. An increase in tumor marker value was compared with PETCT findings and disease relapse. Sensitivity and
specificity for both tests were calculated with respect to clinical outcome.
Results: Disease relapse was detected in 16 out of 45 BC patients. CA15-3 and PETCT showed 75% sensitivity with a
specificity percentage of 76% for CA15-3 and 79% for PETCT. Serum CA15-3 expression levels were significantly
higher in BC patients with multiple metastatic sites with hepatic involvement. Analysis of serial CA15-3 serum levels
showed an increase in CA15-3 3–6 months before PETCT could identify BC patients at risk for relapse (AUC = 0.81).
Moreover, patients receiving anti-hormonal or chemotherapy medications with negative PETCT and positive CA15-3
relapsed after a median time of 158 days compared to patients who were negative for both tests and who were
free from disease for at least 1 year.
Conclusions: Our results showed that serial increases in CA15-3 can be used to predict positive PETCT results in BC
patients during follow-up. Increased levels of CA15-3 may be considered an early warning sign in patients needing
accurate molecular imaging investigations, as they are at higher risk of recurrence. In cases of elevated levels,
multiple lesions or liver involvement may exist. Also, patients receiving chemotherapeutic or anti-hormonal treatment
who have negative PETCT scans and increased CA15-3 serum levels should be considered at risk for relapse, because the
CA15-3-linked biochemical signal of the presence of a tumor can predict positive metabolic imaging.
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Breast cancer (BC) is by far the most frequent type of can-
cer in women worldwide, but it is associated with relatively
lower mortality rates, as it ranks fifth in cancer-related
deaths overall [1]. These data mostly reflect improvements
in the treatment of BC recurrences and metastases due to
the availability of new drugs and biological therapies [1].
The efficacy of these medications is greatly improved if re-
current or metastatic disease is detected early [2]. Thus,
during recent years, the introduction of 2-deoxy-2-[18 F]
fluoro-D-glucose (18FDG) positron emission tomography
(PET) with integrated computed tomography (CT), known
as PETCT, has become a helpful tool for this purpose [3].
Indeed, PETCT is able to detect recurrences at very early
stages of development due to the abnormal uptake of
18FDG by neoplastic cells before the onset of morphologic
changes that are detectable with conventional imaging
[4,5]. Whole-body PETCT is a very useful diagnostic tech-
nology, especially when BC recurrence is suspected in
asymptomatic patients with elevated tumor marker levels
and negative conventional imaging results [6-8]. In this
case, the early detection of disease relapse greatly improves
the chances for successful treatment. However, despite this
important feature, an intense debate remains among sci-
entific organizations about the value of tumor markers
in predicting clinical or radiological findings of disease
relapse [9]. To date, only the European Group on
Tumor Markers (EGTM) suggests that an increase in
serum CA15-3 often predicts clinical or radiological
signs of disease recurrence in BC patients, with an esti-
mated lead time of 2–9 months [10-12].
In this study, we performed a retrospective analysis of
the medical records of 45 BC patients with suspicion of
recurrence who underwent both PETCT scans and serial
measurements of CA15-3 to asses if: i) a serial increase
in CA15-3 was optimal for recommending addressing
PETCT examination of BC patients during follow-up;
ii) CA15-3 serum levels could be correlated with PETCT
findings in terms of number of detectable FDG positive
lesions; iii) elevated CA15-3 serum levels are also pre-
dictive of disease relapse in patients who at the end of
their therapeutic treatment have a negative PETCT re-
sult and are positive for CA15-3.
Materials and methods
Patient population
A review of the biochemistry and molecular imaging da-
tabases was performed at the SDN Institute to select BC
patients who underwent both PETCT scans and serial
CA15-3 serum level measurement for suspicion of re-
currence as required for their clinical care protocol be-
tween January 2011 and December 2012. Based on these
criteria, we selected one male and 44 female patients
with a median age of 60 years (range 39–85 years) whounderwent clinical follow-up in the routine oncology
setting. Sixteen out of 45 BC patients experienced a BC
relapse, 11/16 patients underwent chemotherapy, 1/16
underwent chemotherapy with Herceptin®, 2/16 under-
went surgery plus chemotherapy, and 2/16 started or
continued hormonal therapy (Tamoxifen or inhibitors of
aromatase). Among the patients without disease relapse,
6/29 continued hormonal therapy, and the remaining
patients were followed up after surgical or chemothera-
peutic intervention. All patients without signs of disease
relapse remained free from disease for at least 1 year
after the PETCT scans and CA15-3 measurements that
were performed in this study.
Informed consent for PETCT examination was ob-
tained from all patients. This study was approved by the
Ethics Committee of IRCCS Fondazione SDN (Naples,
Italy). Because this was a retrospective study and all
procedures had already been performed for clinical pur-
poses, our Institutional Review Board (Ethics Committee
of IRCCS Fondazione SDN) did not require further pa-
tient approval or informed consent for the review of pa-
tient files or images.
18FDG PETCT Imaging
PETCT scans were performed with a hybrid system (Gem-
ini TF Philips Healthcare, Best, Netherlands). Before the
PETCT scan, each patient fasted for at least 6 h, and the
blood glucose level (glucose level below 7.78 mmol/L) was
measured prior to injection of 4–5 MBq/kg of 18FDG. One
hour after injection, the PETCT scan was acquired in 3D
and was thus fully reconstructed with the line-of-response
based row-action maximum-likelihood algorithm (LOR
RAMLA). In particular, acquired images were processed to
obtain trans-axial, sagittal, and coronal views. The PETCT
system obtains precise anatomic localization of 18FDG
positive lesions, and CT-based attenuation correction
ensures an accurate quantitative measurement of the stan-
dardized uptake value (SUV) of lesions. During the acquisi-
tion, the patient was in a supine position with both arms
brought together above the head. All acquired images were
reviewed with a Xeleris workstation (General Electric
Heathcare, Milwaukee, WI, USA) and interpreted by an ex-
perienced nuclear medicine physician and a radiologist to
obtain a final diagnosis by consensus. Regions showing
focally prominent FDG-PET uptake compared with sur-
rounding tissues and not related to normal physiologic
uptake were considered positive for malignancy. The
Xeleris workstation produces SUVs that are calculated
as the ratio of the tissue radioactivity concentration
measured with PET and the injected dose divided by the
patient’s weight. In the reviewing procedure, physicians
assigned the maximum SUV to each lesion within the
region of interest (SUVmax). Furthermore, CT provides
accurate information about the anatomical localization
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volumetric characterization of lesion burden was made
[13], considering a metabolic tumor volume (MTV)
with a threshold of 40% of the maximum signal intensity
(MTV40). Therefore, a voxel with an SUV between 40%
of SUVmax and SUVmax was considered to be part of
the lesion.
Measurement of CA15-3
The CA15-3 serology test was performed at the laboratory
of clinical biochemistry at the SDN Institute in accordance
with the manufacturer’s protocols and reference intervals.
Specifically, all serum tumor markers were measured on
an ADVIA Centaur® XP automated Immunoassay System
(SIEMENS Healthcare Diagnostics Inc., Tarrytown, NY,
USA). The threshold value provided by the supplying
company for CA15-3 was 25 UI/mL. For each patient,
three serial serum CA15-3 determinations performed at
6–9 months (270 ± 102 days), 3–6 months (139 ± 79 days),
and 0–3 months (20 ± 30 days) before PETCT were recov-
ered from the SDN archives.
Statistical data analysis
All statistical analyses were performed using GraphPad
Prism version 4.0 (GraphPad Software, La Jolla, CA, USA).
Continuous data were presented as the mean ± standard
deviation or median ± interquartile range. Statistical signifi-
cance was evaluated with the Mann–Whitney U-Test for
unpaired data or the Student’s t test as appropriate. Area
Under the Curve (AUC) was calculated with Receiving
Operating Characteristic (ROC) analysis, to study the
variation in CA15-3 to better predict a positive PETCT
result at different time points.
Results and discussion
The daily clinical experiences in monitoring BC patients
after primary therapy demonstrate that any significant
increase in tumor markers, even in the absence of other
clinical or instrumental signs of cancer, justifies PETCT
examination [14,15]. Nevertheless, the usefulness of bio-
markers in monitoring BC patients after primary therapy
is still the subject of intense debate in the scientific lit-
erature [16]. In particular, the current guidelines of the
American Society of Clinical Oncology do not recom-
mend measurement of serum biomarkers such as Carci-
noEmbryonic Antigen (CEA) and CA15-3 for monitoring
BC patients during follow-up [17]. Conversely, the EGTM,
in agreement with the National Academy of Clinical Bio-
chemistry guidelines and the European Association for
Nuclear Medicine, suggests that increasing levels of serum
tumor markers may often precede clinical or radiological
signs of disease recurrence [18,19]. In addition to these
recommendations, a growing number of scientific papers
have re-evaluated the value of increased CA15-3 serumlevels for early detection of recurrence, showing that
serum determination of CA15-3 improves the diagnostic
accuracy of PETCT [20-23].
Given these reports, we decided to perform a retro-
spective study of a group of 45 BC patients who were
followed up in our institution with PETCT scans and
measurement of CA15-3 serum levels according to their
clinical care protocol. Disease relapse was documented
by prolonged clinical or radiological follow-up in 16 out
of 45 patients (35%). In relapsing patients, the CA15-3
levels were ≥25 UI/mL in 12 out of 16 cases (75% sensi-
tivity), whereas in disease-free patients, CA15-3 levels
were <25 UI/mL in 22 out of 29 cases (76% specificity).
The CA15-3 positive and negative predictive values were
63% and 84%, respectively. PETCT was able to detect re-
currence or metastatic disease in 12 out of 16 patients
(75% specificity), whereas in 23 out of 29 (79%) non-
relapsing BC cases, PETCT did not show pathological
SUV sites. The positive and negative predictive values of
PETCT were 67% and 85%, respectively.
For diagnostic integration of the two methods, we corre-
lated the CA15-3 serum levels with PETCT findings and
found a significant increase in the median CA15-3 serum
levels (p-value <0.05) in patients with multiple metastatic
sites (8 out of 12 patients with positive PETCT) compared
to those with a single metastatic site (4 out of 12 patients
with positive PETCT). Specifically, in relapsing BC patients
with multiple metastatic sites, the median value of CA15-3
was 49.1 UI/mL (range 8.2–298.4 UI/mL), whereas in
those with a single metastatic site, the median value was
17.4 UI/mL (range 5.8–44.2 UI/mL).These data showed
that, according to previous studies, elevated levels of
CA15-3 are predictive of disease dissemination rather
than local recurrence [24-26]. In addition, the highest
serum levels of CA15-3 (≥120 UI/mL) were found in
patients with hepatic involvement in agreement with
Nicolini and colleagues [27].
Based on these findings, we asked if CA15-3 provides
earlier detection of a relapse in comparison to PETCT. To
test this idea according to other studies [22,26], for each
patient, we collected three serial serum CA15-3 measure-
ments from our internal archives. As shown in Figure 1,
the serial measurements were performed at 6–9 months
(270 ± 102 days), 3–6 months (139 ± 79 days), and 0–3
months (20 ± 30 days) before the PETCT scan. In patients
with a positive PETCT scan, the mean CA15-3 value 6–9
months before the PETCT scan was 40.01 ± 42.40 UI/mL
(median 23.3 UI/mL, range 6.2–159 UI/mL), 3–6 months
before the PETCT scan was 46.17 ± 42.97 UI/mL (median
29.20 UI/mL, range 8–155 UI/mL), and 0–3 months be-
fore the PETCT scan was 52.64 ± 68.33 UI/mL (median
31.9 UI/mL, range 5.8–298.4 UI/mL). As expected, in pa-
tients with a negative PETCT scan, the mean CA15-3
values 6–9 months, 3–6 months, and 0–3 months before
Figure 1 Correlation between the trend in serial CA15-3 measurements and PETCT findings. The bar plot shows the mean CA15-3 serum
levels at 0–3, 3–6, and 6–9 months prior to PETCT. Dotted line indicates CA15-3 cut-off (25 UI/mL). The P-value was determined with an
unpaired t-test.
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cases the increase in the percentage of CA15-3 between
the time spans of 3–6 and 6–9 months was 15%, whereas
that between 0–3 and 3–6 months was 14%. Moreover,
using ROC curve analysis, we found that the AUC value
for CA15-3 was 0.81 for both 0–3 and 3–6 months before
the PETCT scan and 0.77 6–9 months before the scan.
According to Evangelista et al. [22], these results indicate
that an increase in CA15-3 3–6 months (139 ± 79 days)
before PETCT could already identify BC patients at risk
for relapse, and thus, the biochemical signal of theFigure 2 Right side: example of a patient with negative PETCT finding
UI/mL; left side: the same patient 6 months later with positive PETCT
levels of 116.8 UI/mL. Arrows indicate the metastatic sites.presence of a tumor could predict positive metabolic
imaging of disease. This conclusion is interesting espe-
cially in BC patients who undergo PETCT examination
while receiving anti-hormonal or chemotherapy medi-
cations. In fact, these medications reduce the tumor
avidity for FDG and consequently, the sensitivity of
PETCT [22]. In our series, 10 BC patients were receiving
therapeutic treatment, and PETCT and CA15-3 serum
levels were obtained every 6 months. In four of those 10 pa-
tients, PETCT was negative and CA15-3 serum levels were
higher than 25 UI/mL (45.3, 84.6, 27.8, and 26.2 UI/mL).s (a: coronal view; b: transaxial view) and CA15-3 levels of 45.3
findings (c: coronal view; d: transaxial view) as well as CA15-3
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and showed an increase in the CA15-3 serum levels
(116.8, 96.4, 44.2, and 30 UI/mL) and a positive PETCT
scan. Conversely, the control group, which was composed
of the remaining patients (n = 6) who had a negative
PETCT scan and low CA15-3 levels, was free from disease
even after 1 year of follow-up. Figure 2 shows an example
patient at the end of chemotherapy treatment with a
negative PETCT result and a positive CA15-3 value
(45.3 UI/mL). This patient relapsed after 6 months and
showed positive PETCT findings and CA15-3 levels that
had increased 2.5-fold (116 UI/mL). These results show
for the first time the usefulness of CA15-3 for identify-
ing patients with false negative PETCT scans that re-
quire a stringent follow-up due to a risk for developing
disease relapse.
Conclusions
Our study, although performed with a small case series,
shows that a serial increase in CA15-3 can predict posi-
tive PETCT results and detect the presence of residual
disease in patients during therapeutic treatment who
show negative PETCT results. The diagnostic integration
of CA15-3 with PETCT could be a useful strategy for opti-
mizing clinical protocols for early detection of disease re-
lapse. Indeed, the monitoring of CA15-3 may be useful for
correct timing of performing PETCT for early detection of
cancer lesions and initiation of appropriate therapeutic
intervention. Further studies are necessary to identify
additional serum biomarkers that can be integrated with
modern molecular imaging instruments. Indeed, CA15-
3 is not useful in cases of local regional recurrences or
for screening purposes. Innovative biomarkers such as
microRNAs and circulating tumor DNA are promising,
however, they need to be validated and translated into
clinical practice.
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